Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field

Recruiting N/A Interventional Study
Lung Neoplasms Surgery
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
1,120 (estimated)
Sponsor
The First Affiliated Hospital with Nanjing Medical University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study aims to investigate whether segmentectomy had non-inferiority long-term oncological effects (disease-free survival and overall survival) compared with lobectomy in the treatment of patients with early-stage non-small cell lung cancer ≤ 2 cm in the middle third of lung field.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Patient aged 18-75 years old; 2. 6 mm ≤ tumor size ≤ 20 mm; 3. 0.25 \< CTR \< 1; 4. Center of tumor located in the middle third of the lung field; 5. ECOG score of 0,1 or 2; 6. Lung function (FEV1 ≥ 1 L and ≥ 70%); 7. Both lung segmentectomy and lobectomy could achieve R0 res…
Contacts

Zhihua Li, M.D.

+86-025-68303743

lizhihua_njmu@126.com

CONTACT

Weibing Wu, M.D.

+86-025-68303743

wuweibing95@163.com

CONTACT